Home › Research › Biomarkers
CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer's Disease
Jesús Garcia Castro, Helena Méndez Del Sol, Olaia Rodríguez Fraga, María Hernández Barral, Soledad Serrano López, Ana Frank García, Ángel Martín Montes. Neuro-degenerative diseases, 2023-05-15
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Participants were classified as hyposecretors (n = 22, median Aβ40 5,870.500 pg/mL, interquartile range [IQR] 1,431), normosecretors (n = 47, median Aβ40 10,817 pg/mL, IQR 3,622), and hypersecretors (n = 7, 19,767 pg/mL, IQR 3,088). The distribution of positive phosphorylated Tau (p-Tau) varied significantly between subgroups and was more common in the normo- and hypersecretor categories (p = 0.003). Aβ40 and p-Tau concentrations correlated positively (ρ = 0.605, p < 0.001). No significant differences were found among subgroups regarding age, initial MoCA score, initial GDS stage, progression to the dementia stage, or changes in the MoCA score. In this study, we found no significant differences in clinical symptoms or disease progression in AD patients according to their CSF Aβ40 concentration. Aβ40 was positively correlated with p-Tau and total Tau concentrations, supporting their potential interaction in AD pathophysiology.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Castro, J. G., Del Sol, H. M., Fraga, O. R., Barral, M. H., López, S. S., García, A. F., et al. (2022). CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer's Disease. Neuro-degenerative diseases. https://doi.org/10.1159/000530907
Vancouver
Castro JG, Del Sol HM, Fraga OR, Barral MH, López SS, García AF, et al. CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer's Disease. Neuro-degenerative diseases. 2022. doi:10.1159/000530907. PMID: 37231965.
BibTeX
@article{castro2022-37231965,
author = {Castro, Jesús Garcia and Del Sol, Helena Méndez and Fraga, Olaia Rodríguez and Barral, María Hernández and López, Soledad Serrano and García, Ana Frank and Montes, Ángel Martín},
title = {{CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer's Disease}},
journal = {Neuro-degenerative diseases},
year = {2022},
doi = {10.1159/000530907},
pmid = {37231965},
url = {https://doi.org/10.1159/000530907}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Participants were classified as hyposecretors (n = 22, median Aβ40 5,870.500 pg/mL, interquartile range [IQR] 1,431), normosecretors (n = 47, median Aβ40 10,817 pg/mL, IQR 3,622), and hypersecretors (n = 7, 19,767 pg/mL, IQR 3,088).
- The distribution of positive phosphorylated Tau (p-Tau) varied significantly between subgroups and was more common in the normo- and hypersecretor categories (p = 0.003).
- Aβ40 and p-Tau concentrations correlated positively (ρ = 0.605, p < 0.001).
- No significant differences were found among subgroups regarding age, initial MoCA score, initial GDS stage, progression to the dementia stage, or changes in the MoCA score.
- In this study, we found no significant differences in clinical symptoms or disease progression in AD patients according to their CSF Aβ40 concentration.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designretrospective cohort
- Participants22
- Evidence strengthModerate
How this study scored 64/100
Published in a peer-reviewed journal, and it is a retrospective cohort study, reconstructed from past records. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 36 of the 56 points we could judge it on, which is 64 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuro-degenerative diseases) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A retrospective cohort study, reconstructed from past records |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 22 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37231965) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 36 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 36 of the 56 points we could judge it on is 64 out of 100. |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.